Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2018-05-14EMA Authorised: Prandin (repaglinide) — Novo Nordisk A/S
The EMA has authorised Prandin (repaglinide) for Type 2 diabetes, with Novo Nordisk A/S as the marketing authorisation holder.
-
FDA approval · 2018-04-24FDA Approved: AFREZZA — Supplemental Application (Mannkind Corporation)
FDA approved a supplemental application for AFREZZA (insulin human) from MannKind Corporation.
-
FDA approval · 2018-04-17FDA Approved: PIOGLITAZONE — Original Application (Solco Healthcare LLC)
FDA approves Solco Healthcare LLC's original application for pioglitazone as a generic product under ANDA 207806.
-
FDA approval · 2018-03-26FDA Approved: TOUJEO — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approves a supplemental application for Toujeo (insulin glargine) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2018-03-26FDA Approved: TRESIBA — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for TRESIBA (insulin degludec) filed by Novo Nordisk.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-03-16FDA Approved: METFORMIN ER 500 MG — Original Application (Quallent Pharmaceuticals Health LLC)
FDA approved Quallent Pharmaceuticals Health LLC's metformin extended-release tablets (500 mg and 750 mg) under ANDA 209313 for type 2 diabe…
-
FDA approval · 2018-03-06FDA Approved: FIASP — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for FIASP (insulin aspart injection) by Novo Nordisk. The approval results in an updated labeling fo…
-
FDA approval · 2018-02-09FDA Approved: JANUMET — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for JANUMET (sitagliptin/metformin hydrochloride) from Merck Sharp & Dohme LLC.
-
FDA approval · 2018-02-09FDA Approved: JANUMET XR — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for JANUMET XR (sitagliptin and metformin hydrochloride) submitted by Merck, indicating an expanded …
-
FDA approval · 2018-02-09FDA Approved: JANUVIA — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for JANUVIA (sitagliptin) from Merck Sharp & Dohme LLC.
-
FDA approval · 2018-01-02FDA Approved: INVOKAMET XR — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVOKAMET XR, a fixed-dose extended-release combination of canagliflozin and metformin hydro…
-
FDA approval · 2017-12-27FDA Approved: GLIMEPIRIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for glimepiride submitted by Rising Pharma Holdings, Inc., expanding the regulatory status of th…
-
FDA approval · 2017-12-21FDA Approved: ALOGLIPTIN AND PIOGLITAZONE — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
The FDA approved a supplemental application for the alogliptin and pioglitazone fixed-dose combination from Padagis Israel Pharmaceuticals L…
-
FDA approval · 2017-12-21FDA Approved: PIOGLITAZONE AND GLIMEPIRIDE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application from Prasco Laboratories for a Pioglitazone and Glimepiride product. This adds a fixed-dose combinat…
-
FDA approval · 2017-12-19FDA Approved: STEGLATRO — Original Application (Merck Sharp & Dohme LLC)
FDA approved STEGLATRO (ertugliflozin) in its original application for adults with type 2 diabetes mellitus to improve glycemic control, inc…
-
FDA approval · 2017-12-19FDA Approved: STEGLUJAN — Original Application (Merck Sharp & Dohme LLC)
FDA approved the original application for Steglujan, a fixed-dose combination of ertugliflozin and sitagliptin, for improving glycemic contr…
-
FDA approval · 2017-12-19FDA Approved: SEGLUROMET — Original Application (Merck Sharp & Dohme LLC)
FDA approved Segluromet (ertugliflozin and metformin hydrochloride) under an original application by Merck Sharp & Dohme LLC for the treatme…
-
FDA approval · 2017-12-13FDA Approved: JARDIANCE — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for Jardiance (empagliflozin) submitted by Boehringer Ingelheim Pharmaceuticals, Inc., resulting in …
-
FDA approval · 2017-12-13FDA Approved: SYNJARDY — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for SYNJARDY (empagliflozin and metformin hydrochloride) submitted by Boehringer Ingelheim Pharm…
-
FDA approval · 2017-12-13FDA Approved: SYNJARDY XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for SYNJARDY XR (empagliflozin/metformin hydrochloride extended-release) from Boehringer Ingelhe…
-
FDA approval · 2017-12-12FDA Approved: TRULICITY — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for TRULICITY (dulaglutide) submitted by Eli Lilly and Company.
-
FDA approval · 2017-12-12FDA Approved: XULTOPHY 100/3.6 — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for XULTOPHY 100/3.6, a fixed-ratio combination of insulin degludec and liraglutide, by Novo Nor…
-
FDA approval · 2017-12-11FDA Approved: ADMELOG — Original Application (Sanofi-Aventis U.S. LLC)
FDA approves ADMELOG (insulin lispro) from Sanofi-Aventis U.S. LLC under a Biologics License Application.
-
FDA approval · 2017-12-05FDA Approved: OZEMPIC — Original Application (Novo Nordisk)
The FDA approves Ozempic (semaglutide) under NDA209637 for adults with Type 2 diabetes mellitus to improve glycemic control (original applic…
-
FDA approval · 2017-10-31FDA Approved: METFORMIN HYDROCHLORIDE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved an original application for METFORMIN HYDROCHLORIDE from Macleods Pharmaceuticals Limited, adding a generic metformin hydrochlo…